Las Vegas—Treatment with biologics and immunosuppressants does not increase the risk for cancer progression or recurrence in patients with inflammatory bowel disease and a history of active or recent, prior cancer, according to a new study.
This new research adds to a growing body of evidence supporting the safety of these drugs in an aging population of IBD patients. “With an aging population, the risk of cancer among our IBD patients will increase, and this question will become